论文部分内容阅读
目的:观察急性心肌梗死(AMI)静脉溶栓治疗的疗效及预后。方法:选用我院2002年1月～2006年2月来收治AMI患者60例,其中男性35例,女性25例,全部病例均符合WHO规定的AMI诊断标准,治疗均给予尿激酶(UK)150U～200万U,加生理盐水100ml,静脉点滴,30分钟滴完。结果:本组60例其中33例溶栓成功,再通率达58.3%,胸痛迅速缓解消失42例;发生再灌注心律失常31例,仅3例出现静脉穿刺部位皮映淤斑,无牙齿出血、消化道出血及出血性脑卒中。结论:应用尿激酶溶栓治疗急性心肌梗死是一项安全有效的治疗措施,且发病时间越早溶栓再通成功率越高。
Objective: To observe the efficacy and prognosis of intravenous thrombolysis in patients with acute myocardial infarction (AMI). Methods: Sixty patients with AMI were selected from January 2002 to February 2006 in our hospital, including 35 males and 25 females. All cases were in accordance with the AMI diagnostic criteria prescribed by the WHO. All patients were treated with 150U of urokinase (UK) ~ 200 million U, plus saline 100ml, intravenous drip, 30 minutes drip finished. Results: The thrombolysis was successful in 33 of 60 cases in this group, with a recurrence rate of 58.3% and 42 cases of rapid and complete disappearance of chest pain. There were 31 cases of reperfusion arrhythmia and only 3 cases of venous puncture, , Gastrointestinal bleeding and hemorrhagic stroke. Conclusion: Urokinase thrombolysis in the treatment of acute myocardial infarction is a safe and effective treatment, and the earlier the onset of thrombolytic recanalization, the higher the success rate.